Use of immunotoxicity data in health risk assessments: uncertainties and research to improve the process.
about
Considerations in estimating social and economic impacts of immunotoxic agentsCurrent status of the epidemiologic evidence linking polychlorinated biphenyls and non-hodgkin lymphoma, and the role of immune dysregulationImmunotoxicogenomics: gene expression and immunotoxicology in the age of genomicsInduction of the aryl hydrocarbon receptor-responsive genes and modulation of the immunoglobulin M response by 2,3,7,8-tetrachlorodibenzo-p-dioxin in primary human B cells.Pesticide-induced oxidative stress: perspectives and trends.Immune responses: adverse versus non-adverse effects.2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated disruption of the CD40 ligand-induced activation of primary human B cells.Effects of environmentally-relevant levels of perfluorooctane sulfonate on clinical parameters and immunological functions in B6C3F1 mice.Establishment of an immunoglobulin m antibody-forming cell response model for characterizing immunotoxicity in primary human B cellsMachine learning analysis of the relationship between changes in immunological parameters and changes in resistance to Listeria monocytogenes: a new approach for risk assessment and systems immunology."Omics" Technologies and the Immune System (a) , (b).Suppression of pulmonary host defenses and enhanced susceptibility to respiratory bacterial infection in mice following inhalation exposure to trichloroethylene and chloroform.Inhalation exposure to methylene chloride does not induce systemic immunotoxicity in rats.Genotoxic potency of mercuric chloride in gill cells of marine gastropod Planaxis sulcatus using comet assay.Suppression of antigen-specific antibody responses in mice exposed to perfluorooctanoic acid: Role of PPARα and T- and B-cell targeting.Gene expression alterations in immune system pathways following exposure to immunosuppressive chemicals.
P2860
Q23916681-4EED402F-5912-4496-8ECC-FAFA1CD82EABQ24602309-0085EC8C-8D93-4D6F-B5E8-6032CE7B5AACQ24855057-E0E73D9B-2E6B-4FDA-A943-6A7DB59AB5BAQ34200635-91FE0FFF-BAD5-4565-AAB4-C9843FD3F1BFQ34251850-983BCA4C-D90A-4151-9FEB-14E039E021C2Q34560279-D5E832D5-4015-4E1B-86F8-9D2D18AB5BDDQ35295519-64E2F55F-F5EB-40D0-848C-23A257B23F39Q36245081-8FF405F7-93B8-47E3-ABB7-0BD0C421AF97Q37420414-02467B0D-C97B-4CC7-8D61-0ABF7DF16281Q37463707-8BF53EC2-EC97-40C2-B2B0-2C290635A704Q37658722-147CE2BA-9190-4A39-B852-223E754BBA24Q39953774-67558885-A897-4272-94EE-CB47E4ACCAE0Q44506791-61DD4C93-060C-47FD-9283-B196EEBDF21CQ46761658-901C48AF-0DC4-4EA8-88DD-F691F8CA932BQ51063513-3E76876E-30E2-4CE2-8636-904997C0D8DAQ53584334-C0C049BA-5387-4F9B-8D8C-C714C5F4D7AB
P2860
Use of immunotoxicity data in health risk assessments: uncertainties and research to improve the process.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Use of immunotoxicity data in ...... search to improve the process.
@ast
Use of immunotoxicity data in ...... search to improve the process.
@en
type
label
Use of immunotoxicity data in ...... search to improve the process.
@ast
Use of immunotoxicity data in ...... search to improve the process.
@en
prefLabel
Use of immunotoxicity data in ...... search to improve the process.
@ast
Use of immunotoxicity data in ...... search to improve the process.
@en
P1433
P1476
Use of immunotoxicity data in ...... search to improve the process.
@en
P2093
Selgrade MK
P356
10.1016/S0300-483X(99)00006-2
P407
P577
1999-03-01T00:00:00Z